Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial | Zendy

Jason V. Baker | Zendy; Shweta Sharma | Zendy; Birgit Grund | Zendy; Adam Rupert | Zendy; Julia A. Metcalf | Zendy; Mauro Schechter | Zendy; Paula Munderi | Zendy; Inka Aho | Zendy; Sean Emery | Zendy; Abdel Babiker | Zendy; Andrew Phillips | Zendy; Jens Lundgren | Zendy; James D. Neaton | Zendy; H. Clifford Lane | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

Author(s) -

Jason V. Baker,

Shweta Sharma,

Birgit Grund,

Adam Rupert,

Julia A. Metcalf,

Mauro Schechter,

Paula Munderi,

Inka Aho,

Sean Emery,

Abdel Babiker,

Andrew Phillips,

Jens Lundgren,

James D. Neaton,

H. Clifford Lane

Publication year - 2017

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofx262

Subject(s) - medicine , biomarker , systemic inflammation , proportional hazards model , clinical trial , randomization , antiretroviral therapy , inflammation , human immunodeficiency virus (hiv) , viral load , immunology , biochemistry , chemistry

These data, combined with evidence from prior biomarker studies, demonstrate that IL-6 and D-dimer consistently predict clinical risk across a broad spectrum of CD4 counts for those both ART-naïve and treated. Research is needed to identify disease-modifying treatments that target inflammation beyond the effects of ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research